Sagent Pharmaceuticals, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014	FY2013 12 months to Dec 31, 2013	FY2012 12 months to Dec 31, 2012	FY2011 12 months to Dec 31, 2011
Net revenue
Cost of sales
Gross profit
Operating expenses:
Product development
Selling, general and administrative
Acquisition-related costs
Management transition
Equity in net income of joint ventures
Total operating expenses
Impairment of SCP long-lived assets
Legal Settlement
Termination fee
Gain on previously held equity interest
Income (loss) from operations
Interest income and other income (expense)
Interest expense
Change in fair value of preferred stock warrants
Income (loss) before income taxes
Provision (benefit) for income taxes
Net income (loss)
Net income (loss) per common share:
Basic
Diluted
Weighted-average of shares used to compute net income (loss) per common share:
Basic
Diluted

Comments